Conducted in Jinja between 2021 and 2022, the research highlights potential challenges in treating life-threatening malaria cases in children.
WHAT THE STUDY FOUND
The researchers focused on children aged six months to 12 years who were treated with intravenous artesunate, followed by oral artemether/lumefantrine. Of the 100 children studied, 11 showed signs of artemisinin partial resistance.
This was linked to a genetic mutation known as Pfkelch13 A675V, found in eight children, according to the study published by JAMA Network Open, a monthly open-access medical journal published by the American Medical Association.
Children with this mutation took longer to clear parasites from their blood compared to those without it. On average, parasite clearance time for children with A675V was about five hours, compared to three hours in others. Two children with another variation, C469Y, cleared parasites quickly and did not show resistance.
Despite these findings, the drug regimen was generally effective in most cases. However, two children required extended artesunate treatment—one with the A675V mutation and another without it.
RELAPSES RAISE QUESTIONS
Thirteen children experienced a return of malaria symptoms within 28 days after treatment. Genetic testing revealed that in 10 percent of these cases, the parasite strains matched those from the original infection. This suggests that the initial treatment may not have fully eliminated the infection in some children, regardless of their genetic profile.
IMPLICATIONS FOR MALARIA TREATMENT
This is one of the first studies to document artemisinin resistance in severe malaria cases in Uganda. While artemisinin resistance has been noted before in uncomplicated malaria, its presence in severe cases could complicate treatment guidelines.
The study calls for further research to confirm these findings and explore alternative treatment options. Malaria remains a major health threat in Uganda, particularly for young children, and effective treatment is critical to reducing deaths.
THE BIGGER PICTURE
Malaria caused more than 600,000 deaths worldwide in 2022, with most fatalities in Africa. Uganda is among the countries hardest hit. Ensuring that treatments remain effective is crucial in the fight against the disease. This study raises important questions about the long term reliability of artemisinin-based treatments, especially for severe cases.
The researchers emphasized the need for ongoing monitoring of drug resistance and possibly updating treatment guidelines to ensure better outcomes for children with severe malaria.
inarticle} inarticle}
